Cannabidiol (CBD) is gaining considerable attention in the research community with
promising results in a variety of neuropsychiatric conditions. In particular, there are replicated findings
for the therapeutic effects of CBD on psychotic and anxiety symptoms as well as substance
use disorders, all of which are highly prevalent in patients who present with suicidality. Meanwhile,
there has been a lack of suicide research on cannabidiol. This perspective provides an
overview of the available evidence, potential reasons behind the halt in suicide research on cannabidiol,
and recommendations for future investigations.
Keywords: Cannabidiol, cannabis, marijuana, suicide, adverse events, psychopharmacology.
promotion: free to download
Rights & PermissionsPrintExport